Announcement on Subsidiary’s Drug Entering Phase II Clinical Trials
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Subsidiary’s Drug Entering Phase II Clinical Trials
Filed with SSE · · 2 pages · Chinese
Release
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited on 6ix
Earlier from Guangzhou Baiyunshan Pharmaceutical
- Announcement on Subsidiary’s Drug Entering Key Clinical Trials
- Notice on Convening the 2nd Extraordinary General Meeting in 2025
- Announcement on Subsidiary Obtaining Approval for Marketing of Chemical APIs
- Announcement on Convening the 2025 Semi-annual Performance Briefing
- Announcement on the Completion of Private Fund Filing and Progress of Related Party Transactions
Later from Guangzhou Baiyunshan Pharmaceutical
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on Resolutions of the 29th Meeting of the 9th Board of Directors
- Announcement on Subsidiary’s Drug Entering Phase III Clinical Trials
- Report for Q3 2025
- Announcement on Subsidiary Receiving Vietnamese Drug Registration Certificate
Follow Guangzhou Baiyunshan Pharmaceutical into a list and get an email when it puts out news.
Follow Guangzhou Baiyunshan Pharmaceutical